[Avastin e Lucentis: a matter of drug access, costs and public health]
Epidemiol Prev
.
2020 Jan-Feb;44(1):16-17.
doi: 10.19191/EP20.1.P016.012.
[Article in Italian]
Authors
Antonio Clavenna
1
,
Cinzia Colombo
2
Affiliations
1
Dipartimento di salute pubblica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS.
2
Dipartimento di salute pubblica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS; cinzia.colombo@marionegri.it.
PMID:
32374109
DOI:
10.19191/EP20.1.P016.012
No abstract available
Publication types
News
MeSH terms
Health Care Costs
Health Services Accessibility*
Pharmaceutical Preparations*
Public Health*
Substances
Pharmaceutical Preparations